Employing current GH ultra-sensitive assays, this study aimed to reevaluate prospectively the capacity of the sAOT to predict long-term response to SRLs in a cohort of patients with acromegaly included in the ACROFAST trial. This evidence concerns the gene GH1 and acromegaly.